XCUR Stock Posts

XCUR Exicure5.33+0.43+8.8%

After Hours:13.00+7.67 (+143.9%)

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Globe NewswireMon, 8-Dec 4:30 PM

XCUR Exicure6.89-0.24-3.4%

After Hours:8.20+1.31 (+19.1%)

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Business WireFri, 1-Aug 4:01 PM

XCUR Exicure6.96-0.17-2.4%

After Hours:8.59+1.63 (+23.4%)

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Business WireFri, 1-Aug 4:01 PM

XCUR Exicure10.37-1.84-15.1%

After Hours:15.21+4.84 (+46.7%)

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Business WireWed, 22-Jan 4:01 PM

XCUR Exicure10.37-1.84-15.1%

After Hours:15.76+5.39 (+52.0%)

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Business WireWed, 22-Jan 4:01 PM

XCUR Exicure2.29+0.08+3.6%

After Hours:6.20+3.91 (+170.7%)

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Business WireWed, 18-Sep 4:01 PM